These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19069139)

  • 21. Current status of nephrogenic systemic fibrosis.
    Daftari Besheli L; Aran S; Shaqdan K; Kay J; Abujudeh H
    Clin Radiol; 2014 Jul; 69(7):661-8. PubMed ID: 24582176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal function, nephrogenic systemic fibrosis and other adverse reactions associated with gadolinium-based contrast media.
    Canga A; Kislikova M; Martínez-Gálvez M; Arias M; Fraga-Rivas P; Poyatos C; de Francisco AL
    Nefrologia; 2014; 34(4):428-38. PubMed ID: 25036056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on nephrogenic systemic fibrosis: are we making progress?
    Haemel AK; Sadowski EA; Shafer MM; Djamali A
    Int J Dermatol; 2011 Jun; 50(6):659-66. PubMed ID: 21595657
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000-2006.
    Kendrick-Jones JC; Voss DM; De Zoysa JR
    Nephrology (Carlton); 2011 Feb; 16(2):243-8. PubMed ID: 21272139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
    Martin DR
    Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
    [No Abstract]   [Full Text] [Related]  

  • 27. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction.
    Kay J
    Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii66-9. PubMed ID: 19022818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M; Thuillier D; Lok C; Gras-Champel V
    Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of iodinated contrast induced acute kidney injury (ICI--AKI) - what have we learnt so far?
    Asim M
    Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):753-65. PubMed ID: 19736469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Updates to the ACR Manual on Contrast Media.
    Kodzwa R
    Radiol Technol; 2017 Nov; 89(2):186-189. PubMed ID: 29298922
    [No Abstract]   [Full Text] [Related]  

  • 32. Nephrogenic systemic fibrosis and its impact on abdominal imaging.
    Prince MR; Zhang HL; Prowda JC; Grossman ME; Silvers DN
    Radiographics; 2009 Oct; 29(6):1565-74. PubMed ID: 19959508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrogenic systemic fibrosis: the need for accurate case reporting.
    Spinazzi A; Kirchin MA; Pirovano G
    J Magn Reson Imaging; 2009 May; 29(5):1240; author reply 1241. PubMed ID: 19388104
    [No Abstract]   [Full Text] [Related]  

  • 34. Safe use of iodinated and gadolinium-based contrast media in current practice in Japan: a questionnaire survey.
    Tsushima Y; Ishiguchi T; Murakami T; Hayashi H; Hayakawa K; Fukuda K; Korogi Y; Sugimoto H; Takehara Y; Narumi Y; Arai Y; Kuwatsuru R; Yoshimitsu K; Awai K; Kanematsu M; Takagi R
    Jpn J Radiol; 2016 Feb; 34(2):130-9. PubMed ID: 26662468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrogenic systemic fibrosis: possible mechanisms and imaging management strategies.
    Dawson P
    J Magn Reson Imaging; 2008 Oct; 28(4):797-804. PubMed ID: 18821621
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: chemical structure and stability of gadolinium chelates.
    Idée JM; Port M; Corot C
    Radiographics; 2009 Nov; 29(7):2099. PubMed ID: 19926764
    [No Abstract]   [Full Text] [Related]  

  • 37. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury.
    Kalb RE; Helm TN; Sperry H; Thakral C; Abraham JL; Kanal E
    Br J Dermatol; 2008 Mar; 158(3):607-10. PubMed ID: 18076707
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nephrogenic systemic fibrosis: what the hospitalist needs to know.
    Fine DM; Perazella MA
    J Hosp Med; 2010 Jan; 5(1):46-50. PubMed ID: 20063400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis.
    Barker-Griffith A; Goldberg J; Abraham JL
    Arch Ophthalmol; 2011 May; 129(5):661-3. PubMed ID: 21555622
    [No Abstract]   [Full Text] [Related]  

  • 40. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?
    Weinreb JC; Abu-Alfa AK
    J Magn Reson Imaging; 2009 Dec; 30(6):1236-9. PubMed ID: 19938035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.